Now Playing
News|Videos|November 13, 2023
Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
Insights into diagnosing EGFR-mutant lung cancer and explores evolving first-line treatment strategies, incorporating recent developments, combinations, and clinical trial data, while addressing challenges in testing and patient management.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5